-
1
-
-
33645972882
-
Current concept on the pathogenesis of IBD: crosstalk between genetic and microbial factors. Pathogenic bacteria, altered bacterial sensing or changes in mucosal integrity take "toll"?
-
Lakatos P.L., Fischer S., Lakatos L., Gal I., and Papp J. Current concept on the pathogenesis of IBD: crosstalk between genetic and microbial factors. Pathogenic bacteria, altered bacterial sensing or changes in mucosal integrity take "toll"?. World J Gastroenterol 12 (2006) 1829-1840
-
(2006)
World J Gastroenterol
, vol.12
, pp. 1829-1840
-
-
Lakatos, P.L.1
Fischer, S.2
Lakatos, L.3
Gal, I.4
Papp, J.5
-
2
-
-
33750609696
-
Recent trends in the epidemiology of inflammatory bowel diseases: up or down?
-
Lakatos P.L. Recent trends in the epidemiology of inflammatory bowel diseases: up or down?. World J Gastroenterol 12 (2006) 6102-6108
-
(2006)
World J Gastroenterol
, vol.12
, pp. 6102-6108
-
-
Lakatos, P.L.1
-
3
-
-
38749095183
-
European evidence-based consensus on the management of ulcerative colitis: current management
-
Travis S.P.L., Stange E.F., Lémann M., Øresland T., Bemelman W.A., Chowers Y., et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn Colitis 2 (2008) 24-62
-
(2008)
J Crohn Colitis
, vol.2
, pp. 24-62
-
-
Travis, S.P.L.1
Stange, E.F.2
Lémann, M.3
Øresland, T.4
Bemelman, W.A.5
Chowers, Y.6
-
4
-
-
0030827118
-
A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis
-
Safdi M., DeMicco M., Sninsky C., Banks P., Wruble L., Deren J., et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92 (1997) 1867-1871
-
(1997)
Am J Gastroenterol
, vol.92
, pp. 1867-1871
-
-
Safdi, M.1
DeMicco, M.2
Sninsky, C.3
Banks, P.4
Wruble, L.5
Deren, J.6
-
5
-
-
33745042439
-
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
-
Sutherland L., and MacDonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2 (2006) CD000543
-
(2006)
Cochrane Database Syst Rev
, vol.2
-
-
Sutherland, L.1
MacDonald, J.K.2
-
6
-
-
0036786888
-
Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the committee on safety of medicines
-
Ransford R.A., and Langman M.J. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the committee on safety of medicines. Gut 51 (2002) 536-539
-
(2002)
Gut
, vol.51
, pp. 536-539
-
-
Ransford, R.A.1
Langman, M.J.2
-
7
-
-
33747620510
-
Review article: mode of action and delivery of 5-aminosalicylic acid-new evidence
-
Desreumaux P., and Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid-new evidence. Aliment Pharmacol Ther 24 Suppl. 1 (2006) 2-9
-
(2006)
Aliment Pharmacol Ther
, vol.24
, Issue.SUPPL. 1
, pp. 2-9
-
-
Desreumaux, P.1
Ghosh, S.2
-
8
-
-
36348930927
-
Delayed-release multi-matrix system (MMXTM) mesalazine in ulcerative colitis
-
McCormack P.L., Robinson D.M., and Perry C.M. Delayed-release multi-matrix system (MMXTM) mesalazine in ulcerative colitis. Drugs 67 (2007) 2635-2642
-
(2007)
Drugs
, vol.67
, pp. 2635-2642
-
-
McCormack, P.L.1
Robinson, D.M.2
Perry, C.M.3
-
9
-
-
0034798909
-
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis
-
Kane S.V., Cohen R.D., Aikens J.E., and Hanauer S.B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 96 (2001) 2929-2933
-
(2001)
Am J Gastroenterol
, vol.96
, pp. 2929-2933
-
-
Kane, S.V.1
Cohen, R.D.2
Aikens, J.E.3
Hanauer, S.B.4
-
10
-
-
35348958502
-
Nonadherence in inflammatory bowel disease: results of factor analysis
-
Cervený P., Bortlík M., Kubena A., Vlcek J., Lakatos P.L., and Lukás M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 13 (2007) 1244-1249
-
(2007)
Inflamm Bowel Dis
, vol.13
, pp. 1244-1249
-
-
Cervený, P.1
Bortlík, M.2
Kubena, A.3
Vlcek, J.4
Lakatos, P.L.5
Lukás, M.6
-
11
-
-
33847213152
-
A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis
-
Su C., Lewis J.D., Goldberg B., Brensinger C., and Lichtenstein G.R. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 132 (2007) 516-526
-
(2007)
Gastroenterology
, vol.132
, pp. 516-526
-
-
Su, C.1
Lewis, J.D.2
Goldberg, B.3
Brensinger, C.4
Lichtenstein, G.R.5
-
12
-
-
0033021470
-
Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease
-
Prakash A., and Markham A. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. Drugs 57 3 (1999) 383-408
-
(1999)
Drugs
, vol.57
, Issue.3
, pp. 383-408
-
-
Prakash, A.1
Markham, A.2
-
13
-
-
0033637218
-
Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis
-
Bantel H., Berg C., Vieth M., Stolte M., Kruis W., and Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 95 12 (2000) 3452-3457
-
(2000)
Am J Gastroenterol
, vol.95
, Issue.12
, pp. 3452-3457
-
-
Bantel, H.1
Berg, C.2
Vieth, M.3
Stolte, M.4
Kruis, W.5
Schulze-Osthoff, K.6
-
14
-
-
20944445862
-
Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma
-
Rousseaux C., Lefebvre B., Dubuquoy L., Lefebvre P., Romano O., Auwerx J., et al. Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201 (2005) 1205-1215
-
(2005)
J Exp Med
, vol.201
, pp. 1205-1215
-
-
Rousseaux, C.1
Lefebvre, B.2
Dubuquoy, L.3
Lefebvre, P.4
Romano, O.5
Auwerx, J.6
-
15
-
-
0037309496
-
Peroxysome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice
-
Osawa E., Nakajima A., Wada K., Ishimine S., Fujisawa N., Kawamori T., et al. Peroxysome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 124 (2003) 361-367
-
(2003)
Gastroenterology
, vol.124
, pp. 361-367
-
-
Osawa, E.1
Nakajima, A.2
Wada, K.3
Ishimine, S.4
Fujisawa, N.5
Kawamori, T.6
-
16
-
-
0037330928
-
Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation
-
Brunner M., Assandri R., Kletter K., Tschurlovits M., Corrado M.E., Villa R., et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther 17 (2003) 395-402
-
(2003)
Aliment Pharmacol Ther
, vol.17
, pp. 395-402
-
-
Brunner, M.1
Assandri, R.2
Kletter, K.3
Tschurlovits, M.4
Corrado, M.E.5
Villa, R.6
-
18
-
-
0037253045
-
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis
-
Sandborn W.J., and Hanauer S.B. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 17 (2003) 29-42
-
(2003)
Aliment Pharmacol Ther
, vol.17
, pp. 29-42
-
-
Sandborn, W.J.1
Hanauer, S.B.2
-
19
-
-
33748648599
-
Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study
-
D'Haens G., Hommes D., Engels L., Baert F., van der Waaij L., Connor P., et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 24 October 1 (7) (2006) 1087-1097
-
(2006)
Aliment Pharmacol Ther
, vol.24
, Issue.October 1 7
, pp. 1087-1097
-
-
D'Haens, G.1
Hommes, D.2
Engels, L.3
Baert, F.4
van der Waaij, L.5
Connor, P.6
-
20
-
-
54349103541
-
MMX™ Mesalazine: a pharmacokinetic evaluation of dose proportionality and the effect of food
-
Pierce D., Martin P., Kern M., and Homolka R. MMX™ Mesalazine: a pharmacokinetic evaluation of dose proportionality and the effect of food. Gut 56 Suppl. III (2007) A158
-
(2007)
Gut
, vol.56
, Issue.SUPPL. III
-
-
Pierce, D.1
Martin, P.2
Kern, M.3
Homolka, R.4
-
21
-
-
54349086603
-
Once-daily oral mesalazine (1.5 g/day or 3. 0 g/day) does not accumulate in plasma during repeated dosing-results from a clinical trial
-
Dilger K., Baumgaertner E., and Thomann P. Once-daily oral mesalazine (1.5 g/day or 3. 0 g/day) does not accumulate in plasma during repeated dosing-results from a clinical trial. Gut 56 Suppl. III (2007) A150
-
(2007)
Gut
, vol.56
, Issue.SUPPL. III
-
-
Dilger, K.1
Baumgaertner, E.2
Thomann, P.3
-
22
-
-
18944363679
-
A new oral delivery system for 5-ASA: preliminary clinical findings for MMx
-
Prantera C., Viscido A., Biancone L., Francavilla A., Giglio L., and Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 11 (2005) 421-427
-
(2005)
Inflamm Bowel Dis
, vol.11
, pp. 421-427
-
-
Prantera, C.1
Viscido, A.2
Biancone, L.3
Francavilla, A.4
Giglio, L.5
Campieri, M.6
-
23
-
-
33846242590
-
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis
-
Lichtenstein G.R., Kamm M.A., Boddu P., Gubergrits N., Lyne A., Butler T., et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 5 (2007) 95-102
-
(2007)
Clin Gastroenterol Hepatol
, vol.5
, pp. 95-102
-
-
Lichtenstein, G.R.1
Kamm, M.A.2
Boddu, P.3
Gubergrits, N.4
Lyne, A.5
Butler, T.6
-
24
-
-
33846213645
-
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis
-
[quiz 432-3]
-
Kamm M.A., Sandborn W.J., Gassull M., Schreiber S., Jackowski L., Butler T., et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132 (2007) 66-75 [quiz 432-3]
-
(2007)
Gastroenterology
, vol.132
, pp. 66-75
-
-
Kamm, M.A.1
Sandborn, W.J.2
Gassull, M.3
Schreiber, S.4
Jackowski, L.5
Butler, T.6
-
25
-
-
34250883817
-
MMX Multi-Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials
-
Sandborn W.J., Kamm M.A., Lichtenstein G.R., Lyne A., Butler T., and Joseph R.E. MMX Multi-Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 26 (2007) 205-215
-
(2007)
Aliment Pharmacol Ther
, vol.26
, pp. 205-215
-
-
Sandborn, W.J.1
Kamm, M.A.2
Lichtenstein, G.R.3
Lyne, A.4
Butler, T.5
Joseph, R.E.6
-
26
-
-
54349098750
-
MMX mesalazine therapy for active, mild-to-moderate ulcerative colitis: time to initial symptom resolution
-
Schreiber S., Karlstadt R., Barrett K., and Joseph R.E. MMX mesalazine therapy for active, mild-to-moderate ulcerative colitis: time to initial symptom resolution. Gut 56 Suppl. III (2007) A160
-
(2007)
Gut
, vol.56
, Issue.SUPPL. III
-
-
Schreiber, S.1
Karlstadt, R.2
Barrett, K.3
Joseph, R.E.4
-
27
-
-
42949096844
-
MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations
-
Lichtenstein G.R., Kamm M.A., Sandborn W.J., Lyne A., and Joseph R.E. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther 27 (2008) 1094-1102
-
(2008)
Aliment Pharmacol Ther
, vol.27
, pp. 1094-1102
-
-
Lichtenstein, G.R.1
Kamm, M.A.2
Sandborn, W.J.3
Lyne, A.4
Joseph, R.E.5
-
28
-
-
38749119211
-
® granules) is therapeutic equivalent to a three-times daily dosing of 1 g mesalamine for the treatment of active ulcerative colitis
-
® granules) is therapeutic equivalent to a three-times daily dosing of 1 g mesalamine for the treatment of active ulcerative colitis. Gastroenterology 132 Suppl. S (2007) 898
-
(2007)
Gastroenterology
, vol.132
, Issue.SUPPL. S
, pp. 898
-
-
Kruis, W.1
Gorelov, A.2
Kiudelis, G.3
Racz, I.4
Pokrotnieks, J.5
Horynski, M.6
-
29
-
-
54349095259
-
® Granules) in active ulcerative colitis: a combined analysis from three pivotal controlled studies
-
® Granules) in active ulcerative colitis: a combined analysis from three pivotal controlled studies. Gut 56 Suppl. S (2007) A156
-
(2007)
Gut
, vol.56
, Issue.SUPPL. S
-
-
Kruis, W.1
Greinwald, R.2
Mueller, R.3
-
30
-
-
46349099233
-
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
-
Kamm M.A., Lichtenstein G.R., Sandborn W.J., Schreiber S., Lees K., Barrett K., et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 57 (2008) 893-902
-
(2008)
Gut
, vol.57
, pp. 893-902
-
-
Kamm, M.A.1
Lichtenstein, G.R.2
Sandborn, W.J.3
Schreiber, S.4
Lees, K.5
Barrett, K.6
-
31
-
-
54349121063
-
® mesalamine as the sole medication for the induction and maintenance of remission of mild-to-moderate ulcerative colitis: outcome in patients treated over 14-16 months
-
® mesalamine as the sole medication for the induction and maintenance of remission of mild-to-moderate ulcerative colitis: outcome in patients treated over 14-16 months. Gastroenterology 132 Suppl. S (2007) T1297
-
(2007)
Gastroenterology
, vol.132
, Issue.SUPPL. S
-
-
Kamm, M.A.1
Hanauer, S.B.2
Lichtenstein, G.R.3
Diebold, R.4
Barrett, K.5
Karlstadt, R.G.6
-
32
-
-
0030045124
-
An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized placebo-controlled trial
-
The mesalamine Study Group
-
The mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized placebo-controlled trial. Ann Intern Med 124 (1996) 204-211
-
(1996)
Ann Intern Med
, vol.124
, pp. 204-211
-
-
-
34
-
-
54349117025
-
The effect of endoscopy score at the start of 5-aminosalicylic acid therapy on long-term remission rates in patients with mild-to-moderate ulcerative colitis
-
Lichtenstein G.R., Diebold R., Karlstadt R.G., Barrett K., and Joseph R.E. The effect of endoscopy score at the start of 5-aminosalicylic acid therapy on long-term remission rates in patients with mild-to-moderate ulcerative colitis. Gastroenterology 132 Suppl. S (2007) T1284
-
(2007)
Gastroenterology
, vol.132
, Issue.SUPPL. S
-
-
Lichtenstein, G.R.1
Diebold, R.2
Karlstadt, R.G.3
Barrett, K.4
Joseph, R.E.5
-
35
-
-
54349111890
-
Relationship between time taken to induce remission of acute mild-to-moderate active ulcerative colitis with MMX TM mesalazine and subsequent long-term remission rates: results from three international combined acute and maintenance studies
-
Kamm M.A., Hanauer S.B., Diebold R., Barrett K., and Jospeh R.E. Relationship between time taken to induce remission of acute mild-to-moderate active ulcerative colitis with MMX TM mesalazine and subsequent long-term remission rates: results from three international combined acute and maintenance studies. Gut 56 Suppl. III (2007) A154
-
(2007)
Gut
, vol.56
, Issue.SUPPL. III
-
-
Kamm, M.A.1
Hanauer, S.B.2
Diebold, R.3
Barrett, K.4
Jospeh, R.E.5
-
37
-
-
61849116612
-
®) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial
-
®) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. Gut 56 (2007) OP-G-378
-
(2007)
Gut
, vol.56
-
-
Dignass, A.1
Vermeire, S.2
Adamek, H.3
Befrits, R.4
Bokemeyer, B.5
Börner, N.6
-
38
-
-
57849153149
-
Once daily 3 g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study
-
Kruis W., Laimas J., Pokrotnieks J., Acute G., Mikhailova T.L., Horynski M., et al. Once daily 3 g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology 134 Suppl. S (2008) T1124
-
(2008)
Gastroenterology
, vol.134
, Issue.SUPPL. S
-
-
Kruis, W.1
Laimas, J.2
Pokrotnieks, J.3
Acute, G.4
Mikhailova, T.L.5
Horynski, M.6
-
39
-
-
33748114138
-
Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis
-
Loftus E.V. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am 35 (2006) 517-531
-
(2006)
Gastroenterol Clin North Am
, vol.35
, pp. 517-531
-
-
Loftus, E.V.1
-
40
-
-
33645101335
-
Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study
-
Lakatos L., Mester G., Erdelyi Z., David G., Pandur T., Balogh M., et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 12 (2006) 205-211
-
(2006)
Inflamm Bowel Dis
, vol.12
, pp. 205-211
-
-
Lakatos, L.1
Mester, G.2
Erdelyi, Z.3
David, G.4
Pandur, T.5
Balogh, M.6
-
41
-
-
21344446543
-
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies
-
Velayos F.S., Terdiman J.P., and Walsh J.M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 100 (2005) 1345-1353
-
(2005)
Am J Gastroenterol
, vol.100
, pp. 1345-1353
-
-
Velayos, F.S.1
Terdiman, J.P.2
Walsh, J.M.3
|